web analytics
10.4 C
Munich
Monday, October 25, 2021

Anavex Life Sciences Corp (NASDAQ: AVXL) ANAVEX2-73 (Blarcamesine) Gaining Fast – The Holy Grail of Alzheimer’s Disease (AD).

Anavex Life Sciences Corp (NASDAQ: AVXL) is quickly emerging as one of the most exciting stocks in small caps targeting the holy grail of medicine; Alzheimer’s disease and other neurodegenerative diseases. Alzheimer’s is among the top 10 leading causes of deaths in the United States and represents a wide open colossal market worth billions. While many newsletters have covered the rise of AVXL Microcaspdaily was first on the scene back on April 2, 2015 when AVXL was at $0.20 reporting at the time: “Anavex Life Sciences Corp (OTCMKTS:AVXL) is making an explosive move up on accelerating volume after reversing off $0.15 a share. The stock currently trades at a fraction of the $5 per share it commanded back in 2008. After years of steep decline AVXL has come back to life in a big way; the CEO was recently at the 2015 AD/PD(TM) Conference where Anavex unveiled new promising preclinical data for both ANAVEX 2-73 and ANAVEX 3-71 in two separate presentations.” Since than Microcapdaily has covered the ups and downs and ups of AVXL, the reverse split, the massive short attack and loss of faith by many in the Company and the eventual uplisting from the bulletin boards to a national exchange. 

Under the able leadership of Christopher Missling the successes for AVXL have been adding up as ANAVEX 2-73 received an orphan and a Fast Track designation from the FDA in Rett Syndrome, which has potential to receive a Pediatric Priority Review Voucher, worth millions of dollars. Rett Syndrome is a genetic disease that affects young females and leads to various neurological impairments and has no known cure and only symptomatic treatments. There are between 6,000 and 9,000 US patients. Several weeks ago Anavex reported it has exceeded its enrollment target for the ANAVEX2-73 (blarcamesine) Phase 2b/3 study in Alzheimer’s disease (AD). Topline results are expected by mid-2022. The study exceeded enrollment beyond 450 patients at 52 sites across North America, Europe and Australia using ADAS-Cog (cognition) and ADCS-ADL (activities of daily living and function) as primary endpoints. This double-blind trial is measuring efficacy, tolerability, and safety of two different once daily oral ANAVEX2-73 (blarcamesine) doses or placebo. The countdown to trial completion has begun… 48 weeks To go! 

ANAVEXAnavex Life Sciences Corp (NASDAQ: AVXL) is focused on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX(R)2-73 or blarcamesine, is an agonist of the intracellular sigma-1 chaperone protein. Specifically, it’s a mixed ligand for sigma1/muscarinic receptors.  

SIGMAR1 is an important protein that influences multiple cellular and physiological pathways by being located at the confluence of the mitochondria and the endoplasmic reticulum. According to reports, blarcamesine has “memory-preserving and neuroprotective effects in mice treated with the muscarinic receptor antagonist scopolamine, with synthetic Aβ oligomer injection, or with the NMDA receptor agonist dizocilpine (Villard et al., 2011). Other studies in the Aβ oligomer injection model suggest that blarcamesine may block tau hyperphosphorylation and protect mitochondria (Jan 2013 conference news; Lahmy et al., 2013; Lahmy et al., 2014).” 

Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX(R)2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX(R)2-73 for the treatment of Parkinson’s disease. ANAVEX(R)3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX(R)3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.  

To Find out the inside Scoop on Anavex Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

AVXL

The alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027 according to a new reported published on MarketWatach.– According to the Centers for Disease Control and Prevention, Alzheimer’s is among the top 10 leading causes of deaths in the United States. The death rate for the disease has increased significantly in the U.S. over the past few years. More than 122k deaths were reported in the country due to Alzheimer’s disease in 2018. Highly prevalent among the people with age group of 85 and above, around 5.7 million people are living with Alzheimer’s Disease in the U.S. The World Health Organization (WHO) added that causing disability majorly among older people, Alzheimer’s disease contributes to 60-70% of dementia cases, currently amounting to around 50 million cases globally. Around 10 million new cases are recorded every year. Growing advancements in ever-evolving medical technologies over the years have resulted in remarkable discoveries, further leading to development of effective medicines, treatments and therapies. Alzheimer’s treatment is one such field where continuous research and clinical trials have led to the development of various effective treatments that are not just limited to discovery of drugs but also cognitive trainings and therapies. On the back of continuous research and advancement in medical science to find potential new treatments and helping patients manage their behavioral symptoms. Active healthcare stocks in the markets this week include Longeveron Inc. (NASDAQ: LGVN), Cassava Sciences, Inc. (NASDAQ: SAVA), Biogen Inc. (NASDAQ: BIIB), Athira Pharma, Inc. (NASDAQ: ATHA), Anavex Life Sciences Corp. (NASDAQ: AVXL). 

Microcapdaily first reported on AVXL back on June 11, 2015 when the stock was at $0.30 stating at the time: “Anavex Life Sciences Corp (OTCMKTS:AVXL) recently made a big move up off its $0.15 lows to a high of $0.47 before some healthy consolidation here in the mid $0.30’s range.The stock had been in steep decline in recent years since trading as a high as $4.50 a share back in 2011. AVXL started to move after the CEO presented new promising preclinical data for both ANAVEX 2-73 and ANAVEX 3-7Anavex Life Sciences Corp (OTCMKTS:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases such as Alzheimer’s disease, pain and various types of cancer. AVXL lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 and donepezil (Aricept®), are currently being evaluated in a Phase 2a clinical trial for Alzheimer’s disease.” 

As we have always said here at Microcapdaily on AVXL the Company has got everyone’s attention; the Company is sitting on drugs in development that could potentially turn serveral enormous markets on their head. 

For More On AVXL subscribe to Microcapdaily Right now!

AVXL is quickly emerging as one of the most exciting stocks in small caps targeting the holy grail of medicine; Alzheimer’s disease and other neurodegenerative diseases. Alzheimer’s is among the top 10 leading causes of deaths in the United States and represents a wide open colossal market worth billions. While many newsletters have covered the rise of AVXL Todays Stock in Focus is Anavex Life Sciences Corp (OTCMKTS:AVXL) | Micro Cap Daily when AVXL was at $0.20 reporting at the time: “Anavex Life Sciences Corp (OTCMKTS:AVXL) is making an explosive move up on accelerating volume after reversing off $0.15 a share. The stock currently trades at a fraction of the $5 per share it commanded back in 2008. After years of steep decline AVXL has come back to life in a big way; the CEO was recently at the 2015 AD/PD(TM) Conference where Anavex unveiled new promising preclinical data for both ANAVEX 2-73 and ANAVEX 3-71 in two separate presentations.” Since than Microcapdaily has covered the ups and downs and ups of AVXL, the reverse split, the massive short attack and loss of faith by many in the Company and the eventual uplisting from the bulletin boards to a national exchange.  Under the able leadership of Christopher Missling the successes for AVXL have been adding up as ANAVEX 2-73 received an orphan and a Fast Track designation from the FDA in Rett Syndrome, which has potential to receive a Pediatric Priority Review Voucher, worth millions of dollars. Rett Syndrome is a genetic disease that affects young females and leads to various neurological impairments and has no known cure and only symptomatic treatments. There are between 6,000 and 9,000 US patients. Several weeks ago Anavex reported it has exceeded its enrollment target for the ANAVEX2-73 (blarcamesine) Phase 2b/3 study in Alzheimer’s disease (AD). Topline results are expected by mid-2022. The study exceeded enrollment beyond 450 patients at 52 sites across North America, Europe and Australia using ADAS-Cog (cognition) and ADCS-ADL (activities of daily living and function) as primary endpoints. This double-blind trial is measuring efficacy, tolerability, and safety of two different once daily oral ANAVEX2-73 (blarcamesine) doses or placebo. The countdown to trial completion has begun… 48 weeks To go!  It is generally agreed upon that ehe best treatments for Alzheimer’s center around compounds that have two basic components that have two basic characteristics; they are hydrogen and electron donors. This results in the scavenging of the peroxymigtite and in the partial reversal of oxidation and nitraction. That is why is is important to invest i Anavex (AVXL) and Cyuclo Therapetuics (CYTH); they are taking the right approach even if the outcome is not guaranteed.  We will be updating on AVXL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AVXL.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in AVXL either long or short and we have not been compensated for this article.

 

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.